News >

PARP Inhibitors Continue to Flourish in Advanced Ovarian Cancer

Caroline Seymour
Published: Monday, Oct 07, 2019

Reagan M. Street, MD, MMS, gynecologic oncologist, Texas Oncology

Reagan M. Street, MD, MMS

PARP inhibitors have demonstrated progression-free survival (PFS) gains in the recurrent setting in women with BRCA-mutated advanced ovarian cancer, and now as frontline maintenance therapy in those with a wider scope of homologous recombination deficiencies (HRD), explained Reagan M. Street, MD, MMS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication